1. Assaf C, Dobos G, Zech IM, Doess A, Hibbe T, Jadasz JJ (2022) Versorgungsstruktur der Patienten mit Mycosis fungoides und Sézary-Syndrom in Deutschland - Versorgungsforschung auf Basis von GKV-Routinedaten. J Dtsch Dermatol Ges 20(5):643–652
2. Assaf C, Booken N, Dippel E, Guenova E, Jonak C, Klemke CD, Nicolay JP, Schlaak M, Wobser M, Trautinger F (2022) Chlormethin-Gel zur Behandlung der Mycosis fungoides: Ein Expertenkonsens aus Deutschland, Österreich und der Schweiz (DACH-Region) zum Therapiemanagement. J Dtsch Dermatol Ges 20(5):579–588
3. Assaf C, Waser N, Bagot M, He M, Li T, Dalal M, Gavini F, Trinchese F, Zomas A, Little M, Pimpinelli N, Ortiz-Romero PL, Illidge TM (2021) Contemporary treatment patterns and response in relapsed/refractory cutaneous T‑cell lymphoma (CTCL) across five European countries. Cancers (Basel) 14(1):145
4. Bagot M, Porcu P, Marie-Cardine A, Battistella M, William BM, Vermeer M et al (2019) IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T‑cell lymphoma: an international, first-in-human, open-label, phase 1 trial. Lancet Oncol 20(8):1160–1170
5. Bagot M, Dalle S, Sokol L, Tsianakas A, Musiek A, Ortiz-Romero PL, Poligone B, Duvic M, Elmets C, Leoni M, Dwyer K, Ito T, Herr F, Kim YH (2022) Long-term disease control and safety with the anti-CCR4 antibody mogamulizumab: post-hoc analyses from the MAVORIC trial of patients with previously treated cutaneous T‑cell lymphoma. Dermatol Ther 8:e15634. https://doi.org/10.1111/dth.15634